Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 72
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: Intracranial Hemorrhages, Traumatic Brain Injury
Interventions: SENSE Device; Device
Lead sponsor: Sense Diagnostics, LLC; Industry
Eligibility: 22 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 19
States / cities: Oakland, California • Miami, Florida • Dubuque, Iowa + 15 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Acupressure Therapy, Educational Intervention, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
Interventions: TKM-080301; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more

Conditions: Diabetes
Interventions: Patient Activation and Diabetes Registry; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: injection of mouse TYRP2 DNA; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 7 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: CE-326,597, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 12
States / cities: Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Nivolumab (Cohort A), Ipilimumab (Cohort A, B and C), Hydroxychloroquine (HCQ) (Cohort B), Nab-paclitaxel (nP) (Cohort A, B and C), Gemcitabine (gem) (Cohort A, B and C), NG350A (Cohort C); Drug
Lead sponsor: Cancer Insight, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 3 more

Conditions: OSA, Heart Failure, Myocardial Infarction, Arrhythmia, Cardiac
Interventions: Continuous Positive Airway Pressure; Device
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fontana, California

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: Necitumumab, Paclitaxel, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 33
States / cities: Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 30 more

Conditions: Breast Carcinoma
Interventions: QT Ultrasound Breast Scanner, Questionnaire Administration; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
Interventions: Web/mobile/tablet-based digital decision aid + communication (DA+C) tool; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Baltimore, Maryland • Worcester, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, placebo, sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more

Conditions: Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions: Sugammadex administration; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: COPD
Interventions: Pranayama, Education alone; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Houston, Texas • Colchester, Vermont

Conditions: Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions: automated abdominal binder, Sham binder, Placebo, Midodrine; Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lymphoblastic Lymphoma
Interventions: Prednisone, Vincristine, Daunorubicin, PEG-asparaginase, Erwinia asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Hydrocortisone, Etoposide; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Hernia
Interventions: Prevena Plus; Device
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: WHIM Syndrome
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 292
States / cities: Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more

Search by objective public record fields.

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

The ABC Planning Study: Diabetes and Cardiovascular Risks in Primary Care

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Cardiac Patients

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Sugammadex Titration in Cardiac Surgery Patients

Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease

Automated Abdominal Binder for Orthostatic Hypotension

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Assess the Efficacy of Prevena Plus vs SOC to Closed Incision in Pts Undergoing CAWR and Other Laparotomy Procedures.

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer